Suppr超能文献

反对观点:关于采用新技术和生物标志物来管理急性肾损伤的警示故事和保留意见。

Con: Cautionary tales and reservations about the adoption of new technologies and biomarkers for the management of acute kidney injury.

作者信息

Van Biesen Wim

机构信息

Renal Division, Ghent University Hospital, Ghent, Belgium.

出版信息

Nephrol Dial Transplant. 2017 Mar 1;32(3):414-417. doi: 10.1093/ndt/gfx017.

Abstract

Acute kidney injury (AKI) is an important health-care problem. Over the last decades, many innovative therapies and diagnostic approaches have been tried; however, none of these has been able to confirm consistently that they lead to improved outcomes. Much focus has been placed on intensive care unit (ICU)-associated AKI, whereas the bulk of AKI still concerns patients not in the ICU. Involvement of nephrologists in the care of AKI patients is necessary to further improve outcomes. It is unclear whether new technologies, such as biomarkers, are helpful and could replace nephrology consultation.

摘要

急性肾损伤(AKI)是一个重要的医疗保健问题。在过去几十年中,人们尝试了许多创新疗法和诊断方法;然而,这些方法都未能始终如一地证实它们能带来更好的治疗效果。人们将大量注意力放在了与重症监护病房(ICU)相关的AKI上,而大部分AKI患者仍是非ICU患者。肾病科医生参与AKI患者的护理对于进一步改善治疗效果是必要的。目前尚不清楚诸如生物标志物等新技术是否有用,以及能否取代肾病科会诊。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验